Skip to search formSkip to main contentSkip to account menu

pirfenidone

Known as: 5-methyl-1-phenyl-2-(1H)-pyridone 
An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (4)

AnalgesicsAnti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsPyridones

Narrower (1)

Deskar
NCIt Antineoplastic Agent Terminologypirfenidone 801 MG Oral Tablet [Esbriet]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative.
2018
2018
Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
Introduction The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary… 
Review
2017
Review
2017
Factors Promoting Development of Fibrosis in Crohn’s Disease
The concepts on the pathophysiology of intestinal fibrosis in Crohn’s disease (CD) have changed in recent years. Some years ago… 
Highly Cited
2014
Highly Cited
2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
Pirfenidone, an oral anti‐inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti‐tumor… 
Highly Cited
2011
Highly Cited
2011
Asthma phenotypes and interleukin-13--moving closer to personalized medicine.
Asthma is a chronic inflammatory disease of the airways manifested by reversible airflow obstruction and airway… 
2009
2009
Fluorofenidone attenuates collagen I and transforming growth factor‐β1 expression through a nicotinamide adenine dinucleotide phosphate oxidase‐dependent way in NRK‐52E cells
Aim:  Fluorofenidone (1‐(3‐fluorophenyl)‐5‐methyl‐2‐(1H)‐pyridone) is a novel pyridone agent. The aim of the present study is to… 
2007
2007
p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis.
2001
2001
A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia
The anti‐fibrotic and cytokine modulatory properties of pirfenidone suggest its usefulness in the treatment of myelofibrosis with… 
1997
1997
Pirfenidone Attenuates Bleomycin-Induced Changes in Pulmonary Functions in Hamsters
Abstract The antifibrotic potential of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) was examined in a single intratracheal… 
1997
1997
Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats
Summary: Pirfenidone (PFD) is a new drug which has been shown to prevent or even reverse the extracellular matrix accumulation in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)